ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2025
SEMA6A overexpression inhibited tumor growth and metastasis in colorectal cancer.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Claudin-1 Interacts with CD81 and Promotes the Progression of Colorectal Cancer.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the fourth-leading cause of cancer-related mortality worldwide. Semaphorin 6A (SEMA6A) is a member of the semaphorin family, and its specific biological function in CRC progression remains unclear. Bioinformatics analysis revealed that SEMA6A expression was downregulated in CRC tissues and that low expression of SEMA6A was associated with a poor prognosis. Compared with those in normal colorectal epithelial cells, SEMA6A expression levels were lower in CRC cell lines. CACO2 and SW48 cells were chosen to construct stable SEMA6A-knockdown and SEMA6A-overexpressing cell lines. SEMA6A knockdown promoted CACO2 proliferation. Conversely, SEMA6A overexpression inhibited the proliferation and promoted the apoptosis of SW48 cells. Transwell and wound healing assays demonstrated that SEMA6A overexpression inhibited the invasion and migration ability of SW48 cells. SEMA6A overexpression might impede CRC cell migration and invasion by inhibiting the epithelial-to-mesenchymal transition, as evidenced by the downregulation of N-cadherin expression and the upregulation of E-cadherin expression in SW48 cells. To further validate the role of SEMA6A in CRC progression in vivo, transplanted tumor and liver metastasis mouse models were constructed in nude mice by injecting stable SEMA6A-overexpressing SW48 cell lines. SEMA6A overexpression inhibited tumor growth in SW48 tumor-bearing mice and the expression of Ki-67 in tumor tissues. In addition, SEMA6A overexpression resulted in a marked decrease in liver metastasis of CRC cells, with decreased numbers of hepatic metastatic nodules and infiltration of cancer cells. In summary, SEMA6A overexpression alleviated CRC progression by inhibiting tumor growth and metastasis both in vivo and in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.